Skip to main content
Tag

Chronic Spontaneus Urticaria

chrnic spontaneous urticaria

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data

By Selected articles

Salman A, Demir G, Bekiroglu N.

A retrospective cohort study was performed to investigate the impact of omalizumab on quality of life and its predictors in chronic spontaneous urticaria.

Omalizumab is an effective and well-tolerated treatment alternative for people with chronic urticaria, however there aren’t studies that assess omalizumab impact on quality of life.

The response to omalizumab therapy was evaluated in 42 patients using urticaria activity score over 7 days and urticaria control test. The impairment in quality of life was assessed using Dermatology Life Quality Index and Chronic Urticaria and Quality of Life Questionnaire.

All scores improved from baseline to first month, remaining stable at the third month. Complete responders had better improvement rates in all scores in all scores compared to others. Gender, age and angioedema had no significant effect on quality of life.

Better scores at baseline might be a predictor of a better response to omalizumab and therefore, more improvement in quality of life of patients with chronic urticaria.

This document is only available for registered healthcare professionals

Login

Autoimmune theories of chronic spontaneous urticaria

By Selected articles

Sonali J. Bracken, Soman Abraham and Amanda S. MacLeod

Different theories exist to describe the pathogenesis of chronic spontaneous urticaria. A group of investigators highlighted in this study the evidence surrounding the autoimmune pathogenesis of chronic urticaria, a condition which persists for more than 6 weeks in duration and occurs in the absence of an identifiable provoking factor.

Chronic spontaneous urticaria results from pathogenic activation of mast cells and basophils, which releases proinflammatory mediators of urticaria. Recent data suggests that chronic spontaneous urticaria may involve contributions from both immunoglobin G (IgG)-specific and immunoglobulin E (IgE)-specific autoantibodies against a vast array of antigens that can span beyond those found on the surface of mast cells and basophils, contributing to the severity of the disease and predisposing people to the development of additional autoimmune diseases.

People with chronic spontaneous urticaria mediated by IgE autoantibodies appear to have a faster onset of improvement in response to omalizumab than those with IgG-mediated disease.

This document is only available for registered healthcare professionals

Login
Urticaria Espontánea Crónica (UCE)

Diagnosis, pathogenosis, and treatment of chronic spontaneous urticaria (e-Print)

By Eprint, Selected articles
Allen P, Kaplan M.D.

Diagnosis, pathogenosis, and treatment of chronic spontaneous urticaria (CSU)

High doses of antihistaminic, omalizumab and ciclosporina (in this order) are effective and advisable for Chronic Spontaneous Urticaria (CSU) therapy, an inflammatory skin disease associated to autoimmunity in 45% of patients.

e-Print. Free download until end of purchased units.
This document is only available for registered healthcare professionals.

Login
Biomarcadores urticaria

Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria

By Selected articles
Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E.

Chronic spontaneous urticaria (CSU) is defined by the appearance of wheals and a variable presence of angioedema which persists for at least 6 weeks. Some groups are trying to detect molecules which would be able to help clinicians in reaching a proper diagnosis.

This document is only available for registered healthcare professionals

Login
Close Menu

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR